US 10023916
Markers of tumor cell response to anti-cancer therapy
granted A61PA61P35/00A61P35/02
Quick answer
US patent 10023916 (Markers of tumor cell response to anti-cancer therapy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 3
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P43/00